Literature DB >> 15368475

Restoration of fibroblast growth factor receptor2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells.

Hiroaki Yasumoto1, Akio Matsubara, Kazuaki Mutaguchi, Tsuguru Usui, Wallace L McKeehan.   

Abstract

BACKGROUND: Fibroblast growth factors (FGFs) and their receptors (FGFRs) expedite stromal-epithelial communication in development and homeostasis of the human prostate. Loss of resident epithelial cell FGFR2IIIb that responds to stromal FGF7 and FGF10 accompanies malignant progression of both model animal and human prostate tumors.
METHODS: We examined whether restoration of FGFR2IIIb by transfection in the malignant human prostate tumor PC-3 cell line restored cellular properties associated with less malignant tumors. Cell proliferation, apoptosis, and tumor cell implants were used to monitor malignant properties. Activity of FGFR2IIIb was assessed by immunoblot of FRS2 and p44/42 MAP kinase. Immunochemical analysis of pancytokeratin and lactoferrin expression was utilized to assess changes in cellular differentiation.
RESULTS: Expression of FGFR2IIIb in PC-3 cells by transfection resulted in growth suppression in vitro and reduced tumor formation in vivo concurrent with increased cellular differentiation and apoptosis.
CONCLUSIONS: The results indicate that restoration of FGFR2IIIb to the malignant human prostate epithelial cell prototype PC-3 restores properties associated with nonmalignant tumors and normal cells. This further suggests that epithelial cell resident, homeostasis-promoting FGFR2 may be involved in suppression of malignancy and that restoration may be a candidate for gene therapy of hormone-refractory prostate cancer. 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15368475     DOI: 10.1002/pros.20093

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  23 in total

1.  Identification of RNA-binding proteins that regulate FGFR2 splicing through the use of sensitive and specific dual color fluorescence minigene assays.

Authors:  Emily A Newman; Stephanie J Muh; Ruben H Hovhannisyan; Claude C Warzecha; Richard B Jones; Wallace L McKeehan; Russ P Carstens
Journal:  RNA       Date:  2006-04-07       Impact factor: 4.942

Review 2.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Authors:  Charles J David; James L Manley
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

3.  FGFR1 abrogates inhibitory effect of androgen receptor concurrent with induction of androgen-receptor variants in androgen receptor-negative prostate tumor epithelial cells.

Authors:  Masashi Kobayashi; Yanqing Huang; Chengliu Jin; Yongde Luo; Tetsuji Okamoto; Fen Wang; Wallace L McKeehan
Journal:  Prostate       Date:  2011-03-28       Impact factor: 4.104

4.  Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer.

Authors:  Yu Wu; Jerry Davison; Xiaoyu Qu; Colm Morrissey; Barry Storer; Lisha Brown; Robert Vessella; Peter Nelson; Min Fang
Journal:  Epigenetics       Date:  2016-02-18       Impact factor: 4.528

5.  The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development.

Authors:  Richard Grose; Vera Fantl; Sabine Werner; Athina-Myrto Chioni; Monika Jarosz; Robert Rudling; Barbara Cross; Ian R Hart; Clive Dickson
Journal:  EMBO J       Date:  2007-02-15       Impact factor: 11.598

6.  Fox-2 mediates epithelial cell-specific fibroblast growth factor receptor 2 exon choice.

Authors:  Andrew P Baraniak; Jing R Chen; Mariano A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

7.  Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.

Authors:  Michael G Gartside; Huaibin Chen; Omar A Ibrahimi; Sara A Byron; Amy V Curtis; Candice L Wellens; Ana Bengston; Laura M Yudt; Anna V Eliseenkova; Jinghong Ma; John A Curtin; Pilar Hyder; Ursula L Harper; Erica Riedesel; Graham J Mann; Jeffrey M Trent; Boris C Bastian; Paul S Meltzer; Moosa Mohammadi; Pamela M Pollock
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

8.  Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk.

Authors:  Zhen Zhen Zhao; Pamela M Pollock; Shane Thomas; Susan A Treloar; Dale R Nyholt; Grant W Montgomery
Journal:  Hum Reprod       Date:  2008-02-18       Impact factor: 6.918

9.  Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth.

Authors:  Thomas Amann; Frauke Bataille; Thilo Spruss; Katja Dettmer; Peter Wild; Christian Liedtke; Marcus Mühlbauer; Paul Kiefer; Peter J Oefner; Christian Trautwein; Anja-Katrin Bosserhoff; Claus Hellerbrand
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

10.  Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study.

Authors:  Hongmei Nan; Abrar A Qureshi; David J Hunter; Jiali Han
Journal:  BMC Cancer       Date:  2009-06-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.